DEVELOPMENT AND OPTIMIZATION OF GASTRO-RETENTIVE FORMULATION OF HYDRALAZINE HCL
Abstract
Hydralazine hydrochloride has a half-life of 2 to 4 hours with an oral bioavailability of 26-50%. Since hydralazine has a demethylating effect on various suppressor genes, it can be used in various types of cancer to support chemotherapy. The purpose of this study was to optimize and evaluate floating tablets of hydralazine hydrochloride designed to prolong the gastric residence time and to provide controlled release of the drug for 24 h. The floating tablets of hydralazine hydrochloride were prepared by the wet granulation method. Polymers of hydroxy propyl methyl cellulose (HPMC K100M), HPMC K15M, carbopol 940 and sodium bicarbonate were used as the release retarding agents. This study investigated utility of a 3-factor, 3-level Box-Behnken design and optimization process for floating tablet of Hydralazine with 5 replicates of center points. Amount of HPMC K4 (Hydroxy Propyl Methyl cellulose), amount of sodium bicarbonate were selected as the independent variables whereas total floating time (TFT), T90, % cumulative drug release at 24 hours, and T20, Q1 were selected as dependent variables. Non-Fickian diffusion release transport was confirmed as the release mechanism for the optimized formulation and the predicted values agreed well with the experimental values. Drug excipient compatibility studies were investigated by FTIR, DSC and XRD. The produced tablets exhibited good floating time and controlled drug release over a period of 24 h. The resultant data were critically analyzed to locate the composition of optimum formulations. All predicted values of response variables of optimized formulation demonstrated close agreement with the experimental data during optimization procedure.
Keywords:
Hydralazine, Floating oral dose, Box-Behnken, HPMC K4M, Carbopol 940, Sodium bicarbonateDOI
https://doi.org/10.25004/IJPSDR.2016.080502References
2. Rajput G, Majmudar F, Patel J, Patel K, Thakor R, Patel B. Stomach specific mucoadhesive tablets as controlled drug delivery system: A review work. International Journal of Pharmaceutical Biological Research 2010; 1:30-141.
3. Shinde S, Tadwee I, Shahi S. Gastro Retentive Drug Delivery System: A Review. International Journal of Pharmaceutics 2012; 1(1):01 -13
4. Soni RP, Patel V, Patel RB, Patel M, Patel K, Patel N. Gastroretentive drug delivery systems: a review. International Journal of Pharma World Research 2011; 2(10):1-24.
5. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release 2000; 63(3):235-259.
6. Kim MS, Kim JS, You YH, Park HJ, Lee S, Park JS, et al. Development and optimization of a novel oral controlled delivery system for tamsulosin hydrochloride using response surface methodology. International journal of Pharmaceutics 2007; 341(1-2):97-104.
7. Sauzet C, Claeys-Bruno M, Nicolas M, Kister J, Piccerelle P, Prinderre P. An innovative floating gastro retentive dosage system: Formulation and in vitro evaluation. International journal of Pharmaceutics. 2009; 378(1):23-9.
8. Yang L, Fassihi R. Examination of drug solubility, polymer types, hydrodynamics and loading dose on drug release behavior from a triple-layer asymmetric configuration delivery system. International journal of Pharmaceutics. 1997; 155(2):219-229.
9. Siddikqui S, Bose A. Modulation of drug (Metoprolol succinate) release by inclusion of hydrophobic polymer in hydrophilic matrix. Drug development and industrial pharmacy 2011; 37(9):1016-1025.
10. Prajapati ST, Patel LD. Gastric floating matrix tablets: design and optimization using combination of polymers. Acta pharma. 2008; 58: 221-229.
11. Reynolds JEF. Martindale the Extra Pharmacopoeia. The Royal Pharmaceutical Society: London, 1996, pp. 1218-20.
12. Singh B, Kim K. Formulation and evaluation of famotidine floating tablets. J Control Release 2000; 63: 235-59.
13. Coffin M, Parr A, inventors. Glaxo Inc. Ranitidine solid dosage form. US patent 5 407 687. April 18, 1995.
14. Nazzal S, Khan MA. Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system. Pharm Sci Tech. 2002; 3: 1-9.
15. Rosa M, Zia H, Rhodes T. Dosing and testing in-vitro of a bioadhesive and floating drug delivery system for oral application. Int J Pharm. 1994; 105: 65-70.
16. Chavanpatil MD, Jain P, Chaudhari S, Shear R. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharmaceutics 2006; 304: 178–184.
Published
Abstract Display: 404 
PDF Downloads: 515 
